“For more than two decades, Cenegenics physicians have stood at the intersection of science and advocacy — championing a data-driven, individualized approach to women’s health long before it was mainstream. Today’s announcement validates what we’ve always believed: that evidence, not fear, should guide care.”
— Kristy Berry
An Historic Shift at HHS and FDA
In a landmark announcement today from the U.S. Department of Health and Human Services (HHS), federal health leaders declared the start of a “new era in women’s health.” The Food and Drug Administration (FDA) will remove long-standing black box warnings from menopausal hormone replacement therapy (HRT) products – warnings that, for more than twenty years, discouraged both physicians and patients from considering these treatments.
HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary described the change as a correction of decades of “medical groupthink” that followed the Women’s Health Initiative (WHI) study of 2002 – a study whose results, they explained, were widely misinterpreted and amplified by the media before peer-reviewed publication.
Their message: “The era of ignoring women’s health is over.”
The Science Re-examined
The original WHI study, funded at nearly $1 billion, sought to evaluate the risks and benefits of HRT in post-menopausal women. However, its headline findings, suggesting increased risk of breast-cancer diagnoses, were statistically insignificant and misunderstood. Subsequent follow-ups and meta-analyses, including those published in The New England Journal of Medicine, Journal of the American Medical Association, Cancer, Circulation, Menopause, and the World Journal of Psychiatry, have shown that:
- Women using estrogen alone had a 24% reduction in breast-cancer incidence.
- HRT users experience a 30–50% reduction in cardiovascular mortality and 30% reduction in all-cause mortality.
- Estrogen therapy can reduce fracture risk by 50–60% and may lower risk of Alzheimer’s disease by up to 35%
These findings position estrogen not as a risk amplifier but as a protective agent when initiated early in the menopausal transition – helping to preserve cognitive, cardiovascular, and metabolic function.
The Human Impact
For over two decades, millions of women, including those at the height of their careers and caregiving responsibilities, were steered away from therapy that might have stabilized mood, protected bone density, supported memory, and improved sleep.
According to the FDA’s announcement, fewer than 5% of eligible women currently receive hormone therapy, despite 80% reporting moderate to severe menopausal symptoms lasting eight years or more.
“Menopause is not a niche topic,” said Dr. Sarah Brenner of the FDA. “It’s a deeply human and physiological process. We are at the starting line, not the finish line, of restoring trust and advancing women’s health.”
From Dogma to Data
Dr. Makary characterized the decision as a return to “gold-standard science” after a generation of over-caution. He emphasized that newer research distinguishes between delivery routes – oral, transdermal, and vaginal formulations – and clarifies that low-dose or transdermal estrogens do not carry the same risks once attributed to oral forms combined with outdated synthetic progestins.
This distinction matters: formulations that mirror bioidentical hormones, particularly when physician-supervised and individualized to a woman’s biomarkers, have shown higher efficacy and safety profiles.
The Broader Message: Women’s Health Deserves Precision
Across speakers, one theme was constant: that women’s physiology has too often been simplified or sidelined in clinical research. The call from HHS was to treat women’s hormonal health with the same rigor and respect given to cardiovascular or metabolic medicine.
The announcement was paired with a broader commitment to:
- Increase menopause education in medical training
- Encourage research funding parity for female-specific conditions
- Support clinician re-training on prescribing updated HRT protocols
Dr. Kelly Casperson, a urologist and advocate, summarized the moment:
“He gets treated. She gets dismissed. That ends now.”
Where Cenegenics Fits: Precision Medicine for Women’s Health
At Cenegenics, these changes reinforce what our physicians have long practiced: data-driven, personalized hormone optimization guided by laboratory metrics, not fear.
Through Explore+ Pathways, women gain access to comprehensive panels assessing hormonal balance, inflammation, glucose control, lipid metabolism, and cognitive biomarkers. From this foundation, Cenegenics physicians design individualized programs incorporating:
- Balanced hormone replacement where clinically appropriate
- Evidence-based nutraceuticals supporting estrogen metabolism and bone health
- Precision nutrition and fitness plans that align with metabolic biomarkers
This model mirrors the “start early, personalize precisely” philosophy now being validated at the highest levels of federal health policy.
The Road Ahead
FDA leaders emphasized that this regulatory milestone is not the finish line but the beginning – a shift from fear-based guidance toward functional, evidence-based longevity for women. The agency also signaled new approvals of safer, lower-cost menopausal therapies and committed to continued public education.
For women navigating perimenopause or post-menopause today, the message is one of empowerment: the science supports your right to ask questions, seek clarity, and access care that helps you thrive – not just survive – through every phase of life.
“This shift isn’t just regulatory — it’s cultural. Women’s health is finally being treated with the precision, respect, and personalization it has always deserved. At Cenegenics, we’re proud to have helped lead that change, and even prouder to keep advancing it — one woman, one data point, one success story at a time.”
— Kristy Berry
Learn More
Discover how Cenegenics’ Performance Health Programs, including the Explore+ Women’s HRT Pathway, integrate advanced diagnostics, hormone optimization, and longevity-focused care.
Endnotes
- Women’s Health Initiative (WHI) Study Overview. https://www.nhlbi.nih.gov/science/womens-health-initiative-whi
- Felson, DT et al. “The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women.” The New England Journal of Medicine (1993). https://www.nejm.org/doi/full/10.1056/NEJM199310143291601
- Rossouw, JE et al. “Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease.” Journal of the American Medical Association (JAMA, 2007). https://pubmed.ncbi.nlm.nih.gov/17405972/
- Hodis, HN and Mack, WJ. “Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease.” Cancer (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/
- Cho, Leslie et al. “Rethinking Menopausal Hormone Therapy.” Circulation (2023). https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061559
- Pan, Kathy et al. “Estrogen Therapy and Breast Cancer in Randomized Clinical Trials: A Narrative Review.” Menopause (2022). https://pubmed.ncbi.nlm.nih.gov/35969882/
- Marques Conde, Délio et al. “Menopause and Cognitive Impairment: A Narrative Review of Current Knowledge.” World Journal of Psychiatry (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8394691/
